A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy
Publication
, Journal Article
Rein, L; Rizzieri, DA
Published in: Transplantation and Cellular Therapy
March 2021
Duke Scholars
Published In
Transplantation and Cellular Therapy
DOI
ISSN
2666-6367
Publication Date
March 2021
Volume
27
Issue
3
Start / End Page
S161 / S161
Publisher
Elsevier BV
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rein, L., & Rizzieri, D. A. (2021). A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. Transplantation and Cellular Therapy, 27(3), S161–S161. https://doi.org/10.1016/s2666-6367(21)00198-6
Rein, Lindsay, and David A. Rizzieri. “A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy.” Transplantation and Cellular Therapy 27, no. 3 (March 2021): S161–S161. https://doi.org/10.1016/s2666-6367(21)00198-6.
Rein L, Rizzieri DA. A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. Transplantation and Cellular Therapy. 2021 Mar;27(3):S161–S161.
Rein, Lindsay, and David A. Rizzieri. “A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy.” Transplantation and Cellular Therapy, vol. 27, no. 3, Elsevier BV, Mar. 2021, pp. S161–S161. Crossref, doi:10.1016/s2666-6367(21)00198-6.
Rein L, Rizzieri DA. A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. Transplantation and Cellular Therapy. Elsevier BV; 2021 Mar;27(3):S161–S161.
Published In
Transplantation and Cellular Therapy
DOI
ISSN
2666-6367
Publication Date
March 2021
Volume
27
Issue
3
Start / End Page
S161 / S161
Publisher
Elsevier BV
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences